|

Culmerciclib Clinical Trials

4 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 4

Top Sponsors

  • Sun Yat-sen University1
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Second Affiliated Hospital, Zhejiang University, School of Medicine1
  • Fudan University1

Indications

  • Breast Cancer4
  • Cancer4
  • HER2+ Advanced Breast Cancer1
  • Metastastic Breast Cancer1
  • HER2 Low Breast Carcinoma1

Other4 trials

A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
Phase 2
Culmerciclib in HR+/HER2+ Advanced Breast Cancer
Phase 2
Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
Phase 2
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.